#esmo19: lenvatinib (len) and pembrolizumab (pembro) in advanced endometrial cancer
Published 4 years ago • 3.5K plays • Length 4:02Download video MP4
Download video MP3
Similar videos
-
1:39
dr. makker on synergy between lenvatinib and pembrolizumab in endometrial cancer
-
1:32
dr. makker on safety signals with lenvatinib and pembrolizumab in endometrial cancer
-
57:40
immunotherapy in endometrial cancer: expanding horizons
-
3:24
endometrial cancer health outcomes: pembrolizumab for patients with msi-high endometrial cancer
-
12:35
final study results of keytruda® plus lenvima® for advanced endometrial cancer
-
1:22
dr. zamarin on the role of pembrolizumab in endometrial cancer
-
3:28
keynote-775 subgroup analysis in advanced endometrial cancer
-
0:52
dr. zamarin on lenvatinib plus pembrolizumab in endometrial cancer
-
0:55
dr. backes on safety profile of lenvatinib and weekly paclitaxel in endometrial cancer
-
6:56
#esmo19: positive trial for ovarian cancer: paola-1/engot-ov25
-
0:46
modest response rates in endometrial cancers
-
4:46
#esmo19: forward i (gog 3011) study for platinum-resistant ovarian cancer
-
7:05
#esmo19: prima/engot-ov26/gog-3012 positive study for ovarian cancer
-
0:58
society of gynecologic oncology 50th anniversary: adrienne mallen, md
-
6:21
#esmo19: highlights from proffered paper 1: gynecologic cancers session
-
1:18
incorporating immunotherapy in cervical cancer and endometrial cancer treatment: 2022 esmo florida
-
11:39
transforming second-line immunotherapy for endometrial cancer
-
2:41
leap-011: exploring first-line pembrolizumab lenvatinib for advanced urothelial carcinoma
-
0:53
dr. backes on next steps for lenvatinib and weekly paclitaxel in endometrial cancer